In the field of cardiology, therapeutic apheresis techniques can be used to treat some very challenging and important clinical indications. For some indications, the efficacy of therapeutic apheresis is already well established; for others, studies are currently underway. By far the most extensive experience has been gained using lipoprotein apheresis. Meanwhile, the use of immunoadsorption to treat dilatative cardiomyopathy remains a prominent topic. A new indication is the reduction of C-reactive protein after myocardial infarction. Fresenius Medical Care is working on this area in partnership with the Berlin-based company Pentracor.
1. European Cardiovascular Disease Statistics slide 1.2a and 1.2b, page 20; 2017 Edition; www.ehnheart.org; 07 April 2017
2. Catapano AL et al, Atherosclerosis Oct. 2016; 253: 281–344.
3. Nordestgaard BG et al, Lipoprotein(a): EAS Recommendations for Screening, Desirable Levels and Management, A Handbook for Clinicians, 2012.
4. Doesch et al, Effects of protein A immunoadsorption in patients with chronic dilated cardiomyopathy. Journal of Clinical Apheresis 2010; 25(6): 315–22.
5. Staudt et al, Fcγ-Receptor IIa Polymorphism and the Role of Immunoadsorption in Cardiac Dysfunction in Patients with Dilated Cardiomyopathy. Clinical Pharmacology & Therapeutics 2010; 87(4): 452–8.
6. Wallukat et al, Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas' cardiomyopathy and megacolon. Their potential impact for early risk assessment in asymptomatic Chagas' patients. Journal of the American College of Cardiology 2 February 2010; 55(5): 463–8.
7. Dandel et al, lmmunoadsorption can improve cardiac function in transplant candidates with non-ischemic dilated cardiomyopathy associated with diabetes mellitus. Atherosclerosis Supplements 2015; 18: 124–33.
8. Dandel et al, Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension. Atherosclerosis Supplements 2013; 14: 203–11